The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000792325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
16/06/2026
Date registered
Help: Date registered
1/07/2026
Date last updated
Help: Date last updated
1/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
1/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A two-part Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects with Geographic Atrophy Secondary to age-related macular degeneration (AMD)- Part 2 Randomized, single-masked (subjects), sham-controlled proof-of-activity evaluation
Scientific title
A Phase I/IIa Trial to Evaluate the Safety, Tolerability and Efficacy after single administration of TO-O-1007 (Intravitreal Implant) in subjects with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD) - Part 2 Randomized, single-masked (subjects), sham-controlled proof-of-activity evaluation
Additional trial identifiers [1] 317361 0
TO-I-1007-001
Universal Trial Number (UTN)
Trial acronym
Related trial records
ACTRN12626000680369 is part 1 of this study

Health condition
Health condition(s) studied:
Geographic Atrophy 342330 0
Age Related Macular Degeneration 342331 0
Condition category
Condition code
Eye 338459 338459 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is part 2 of a 2 part study investigating safety and tolerability of a single dose TO-O-1007 intravitreal implantation in participants with GA secondary to AMD. The implant is designed for controlled drug release over a 24-week period.

Part 2 – Phase IIa (Randomized, Single-masked(subject)):
25 Eligible subjects will be randomized in a 2:2:1 ratio to receive:
•Arm 1: TO-O-1007 0.18 mg (Low Dose; 1 implant)
•Arm 2: TO-O-1007 0.36 mg (High Dose; 2implants)
•Arm 3: Sham procedure
Each arm will include 24 weeks of treatment followed 4-week of follow-up.
Intervention code [1] 334378 0
Treatment: Drugs
Description of the comparator or control
Sham intravitreal injection

Sham control will be supplied in sterile, single-use syringes without a needle or implant designed to match the appearance and packaging of the TO-O-1007 syringe to maintain masking. The Principal Investigator will use the sham applicator to mimic the steps of an intravitreal injection without penetration of the eye and without delivery of any investigational product.
Control group
Placebo

Outcomes
Primary outcome [1] 345751 0
To evaluate the safety and tolerability of TO-O-1007 following a single intravitreal administration in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Timepoint [1] 345751 0
Baseline Day 1, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 28 post-dose Concomitant medications Baseline Day 1 (pre and post dose), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 28 post-dose Adverse Events, Ophthalmologic Examination Screening, Baseline Day 1, Week 12 and Week 24 post-dose Physical examinations Screening, Baseline Day 1 (pre and post dose), Week 12 and Week 24 post-dose Vital Signs Screening, Baseline Day 1, Week 12, Week 24 and week 28 post-dose SD-OCT, FAF, Screening, Baseline Day 1 (pre and post dose), Week 12, Week 24 and week 28 post-dose IOP, Slit lamp examination. Baseline Day 1, Week 12 and Week 24 post-dose Safety labs Screening, Week 12 and Week 24 post-dose Fundus Photograph Baseline and Week 24 post-dose FFA
Primary outcome [2] 345752 0
To assess preliminary efficacy of TO-O-1007, including changes over time in geographic atrophy (GA) lesion area following a single intravitreal administration in subjects with (GA) secondary to (AMD)
Timepoint [2] 345752 0
Screening Baseline Day 1, Week 12 and Week 24 FAF
Secondary outcome [1] 463170 0
To assess preliminary efficacy of TO-O-1007, including changes over time in geographic atrophy (GA) lesion area following a single intravitreal administration in subjects with (GA) secondary to (AMD)
Timepoint [1] 463170 0
Screening Baseline Day 1, Week 12 and Week 24 FAF
Secondary outcome [2] 463175 0
To assess preliminary efficacy of TO-O-1007, including changes over time in visual acuity parameters following a single intravitreal administration in subjects with (GA) secondary to (AMD)
Timepoint [2] 463175 0
Baseline Day 1, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 28 post-dose BCVA (ETDRS) Visual Accuity Day 1, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 28 post-dose Low Luminance BCVA (ETDRS) Visual Acuity
Secondary outcome [3] 463177 0
(This is optional depending on site equipment availability) To assess preliminary efficacy of TO-O-1007, including changes over time in macular functional response following a single intravitreal administration in subjects with (GA) secondary to (AMD)
Timepoint [3] 463177 0
Screening, Baseline Day1, Week 12, Week 24 and week 28. Mesopic microperimetry

Eligibility
Key inclusion criteria
The study eye must meet all inclusion criteria. If both eyes are eligible, the eye with the worse visual acuity at the screening visit will be designated as the study eye. If both eyes have equal visual acuity, the right eye will be selected.
1. Subject is male or female and aged greater than or equal to 50 years at the time of informed consent.
2. Subject is willing and able to provide written informed consent and comply with all study-related procedures and assessments.
3. Women of non-childbearing potential (WONCBP), or women of childbearing potential (WOCBP) with:
o A negative urine pregnancy test at screening.
o Agreement to use protocol-defined contraception throughout the study and for at least 60 days after the last dose.
o Agreement to refrain from breastfeeding during the study and for at least 60 days after the last dose.
4. Sexually active male subjects must agree to use protocol-defined contraception and refrain from donating sperm for the duration of the study.
5. Clinical diagnosis of non-foveal geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD), confirmed by both the investigator
and the central reading center.
6. Total GA lesion area must be greater than or equal to 2.5 mm² and less than or equal to 17.5 mm² (equivalent to 1–7 disc areas), as determined by FAF imaging and confirmed by the central reading center.
7. For multifocal GA, at least one focal lesion must be greater than or equal to 1.25 mm² (0.5 disc area), as determined by fundus autofluorescence (FAF) imaging and confirmed by the central reading center, and the total aggregate area must still meet criterion 6.
8. The entire GA lesion must be fully visible in a macula-centered image, not contiguous with any area of peripapillary atrophy, as confirmed by the central reading center.
9. Presence of any hyperautofluorescence pattern in the junctional zone of the GA lesion, as determined by FAF imaging and confirmed by the central reading center.
10. BCVA in the study eye of greater than or equal to 24 ETDRS letters (approximately 20/320 Snellen equivalent), assessed using an ETDRS chart at a standard testing distance
(typically 4 meters) under standard photopic conditions.
11. Adequate ocular media clarity, sufficient pupillary dilation, and stable fixation to allow for high-quality retinal imaging, as determined by the
investigator.
12. Intraocular pressure (IOP) of less than or equal to 21 mmHg in the study eye at screening.
13. Meets all the following microperimetry criteria in the study eye: (if assessed)
The following criteria apply only to subjects undergoing mesopic microperimetry assessment at sites where this assessment is performed.
• Able to detect the fixation target.
• Completion of the 10-2, 68-point test within 30 minutes.
• Fixation losses less than or equal to 20%.
• In the investigator’s opinion, the subject is willing and able to complete
microperimetry assessments.
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Subjects meeting any of the following criteria at screening will be excluded from the study.
1. Prior participation in another interventional clinical study for intravitreal therapies in either eye (including subjects receiving sham) within 6 months prior to the Screening Visit.
2. Prior participation in another interventional clinical study for geographic atrophy in either eye including investigational oral medication and placebo within 6 months prior to the Screening Visit.
3. Prior or planned treatment with any ocular or systemic gene therapy (e.g., AAV-mediated therapies or other genetic modification therapies) at any time prior to Screening or during study participation.
4. Participation in any systemic experimental treatment or any other systemic investigational new drug within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of study treatment.
5. Women who are pregnant or nursing.
6. Known serious allergies to the fluorescein dye used in angiography or to the components of the TO-O-1007 formulation.
7. Absence of hyperautofluorescence in the junctional zone of the GA lesion (i.e., hyperautofluorescence pattern = none).
8. Spherical equivalent of the refractive error demonstrating > 8 diopters of myopia or an axial length > 27 mm.
9. GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy, or toxic maculopathies like plaquenil maculopathy in either eye.
10. Any prior treatment for AMD or any prior IVT treatment for any indication in either eye, except oral supplements of vitamins or minerals within 6 months prior to the Screening Visit.
11. Active CNV in the study eye, as determined by the investigator. The presence of CNV in the fellow eye is permitted. If CNV develops in the study eye during the course of the study, the subject will be withdrawn from the study.
12. Presence of other causes of CNV, including pathologic myopia (spherical equivalent of -8 diopters or more, or axial length of 25 mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, and multifocal choroiditis.
13. Any ocular condition in the study eye that would progress during the course of the study that could affect central vision or otherwise be a confounding
factor.
14. Any sign of diabetic retinopathy in either eye, as determined by the investigator.
15. Presence of intraocular inflammation (greater than or equal to trace cell or flare), macular hole, pathologic myopia, epiretinal membrane, evidence of significant vitreo-macular traction, vitreous hemorrhage or aphakia, as determined by an investigator. (pseudophakia with or without an intact capsule is not an exclusion criteria).
16. Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks.
17. History or evidence of severe cardiac disease (e.g., New York Heart Association Functional Class III or IV), history or clinical evidence of unstable angina, acute coronary syndrome, myocardial infarction, or revascularization within last 6 months, ventricular tachyarrhythmias requiring ongoing treatment.
18. History or evidence of clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation.
19. Clinically significant impaired renal (serum creatinine > 2.5 mg/dL or status post-renal transplant or receiving dialysis) or hepatic function. Subjects with
results outside these ranges may be enrolled after consultation with TheratOcular.
20. History of stroke with residual neurological or visual deficits that may interfere with study assessments, or that may increase medical risk in the opinion of the investigator. Subjects with a prior minor stroke or TIA without residual deficits may be eligible.
21. Any major surgical procedure within 1 month of study entry.
22. Presence or history of idiopathic or autoimmune-associated uveitis in either eye.
23. History of systemic treatment with any anti-complement agent within 9 months prior to the Screening Visit, or an anticipated need for any systemic anti complement agent during the study.
24. Concomitant treatment with any ocular or non-ocular medication that is known to be toxic to the lens, retina, or optic nerve.
25. Intraocular surgery (including lens replacement surgery) within 3 months prior to randomization.
26. History of laser therapy in the macular region.
27. History of any of the following procedures: Posterior vitrectomy, filtering surgery (e.g.,trabeculectomy), glaucoma drainage device, corneal transplant, or retinal detachment.
28. Aphakia or absence of the posterior capsule. Note: YAG laser posterior capsulotomy for posterior capsule opacification done at least 60 days prior to
screening is not exclusionary.
29. Unable to perform microperimetry reliably in the opinion of the investigator.
30. Use of prohibited ocular or systemic medications as listed below, due to potential confounding effects on inflammation, retinal structure, or GA
progression:
• Investigational ocular products: Any investigational periocular, or topical ocular drug within 6 months prior to Screening.
• Systemic immunosuppressive or biologic agents: Chronic systemic immunosuppressants, systemic biologics, or immunosuppressive-dose corticosteroids within 3 months prior to Day 1.
• High-frequency topical ocular anti-inflammatory therapy: Intensive topical corticosteroids or NSAIDs not discontinued = 14 days prior to Day 1.
• High-dose vitamin A or experimental nutraceutical therapy: High-dose vitamin A or non-standard nutraceuticals for AMD/ocular health within 30 days prior to Day 1.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central Randomisation
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer-generated random sequence
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321936 0
Commercial sector/Industry
Name [1] 321936 0
TheratOcular Biotech Australia Pty Ltd
Country [1] 321936 0
Australia
Funding source category [2] 322136 0
Commercial sector/Industry
Name [2] 322136 0
TheratOcular Biotek Co., Ltd.
Country [2] 322136 0
Taiwan, Province Of China
Primary sponsor type
Commercial sector/Industry
Name
TheratOcular Biotech Australia Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 324804 0
None
Name [1] 324804 0
Address [1] 324804 0
Country [1] 324804 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320471 0
Bellberry Human Research Ethics Committee D
Ethics committee address [1] 320471 0
Ethics committee country [1] 320471 0
Australia
Date submitted for ethics approval [1] 320471 0
03/12/2025
Approval date [1] 320471 0
02/03/2026
Ethics approval number [1] 320471 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150582 0
Prof Andrew Chang
Address 150582 0
Sydney Retina and Day Surgery Level 13, Park House, 187 Macquarie Street, Sydney NSW 2000
Country 150582 0
Australia
Phone 150582 0
+61 02 8022 5838
Fax 150582 0
Email 150582 0
Contact person for public queries
Name 150583 0
Weian Chien
Address 150583 0
Metagone: 3F., No. 11, Ln. 77, Xing-Ai Rd., Neihu Dist., Taipei City, Taiwan 11494
Country 150583 0
Taiwan, Province Of China
Phone 150583 0
+886 02 2790 6566 216
Fax 150583 0
Email 150583 0
Contact person for scientific queries
Name 150584 0
Andrew Chang
Address 150584 0
Sydney Retina Clinic and Day Surgery, Level 13, Park House, 187 Macquarie Street Sydney NSW 2000
Country 150584 0
Australia
Phone 150584 0
+61 02 9221 3755
Fax 150584 0
Email 150584 0

Data sharing statement
Will the study consider sharing individual participant data?
No



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.